The Indian Pharmacopoeia Commission is developing a mandatory monograph to standardize the production of semaglutide. This move follows the drug’s patent expiry in March 2026 and the subsequent rise of affordable generic versions from companies like Sun Pharma and Dr. Reddy’s. It aims to ensure patient safety and product consistency in the rapidly growing Indian GLP-1 market.
The Indian Pharmacopoeia Commission (IPC) has initiated the process of drafting a formal, legally binding monograph for semaglutide, the active ingredient in widely used diabetes and weight-loss medications. This new regulatory standard will define the exact requirements for identity, purity, and potency, providing a uniform testing protocol for manufacturers across the country.
This development comes as a direct response to the shifting landscape of the Indian pharmaceutical market. Following the expiry of the global patent for semaglutide on March 20, 2026, the market saw a surge in the launch of affordable generic alternatives. Major domestic pharmaceutical companies, including Sun Pharma, Zydus Lifesciences, Dr. Reddy's Laboratories, Mankind Pharma, Torrent Pharmaceuticals, and Glenmark Pharmaceuticals, have all entered this space, significantly expanding access to the drug.
The rapid growth of the GLP-1 segment—which includes drugs for weight management and diabetes—has been substantial. As of July 2026, the market reached a moving annual total of approximately ₹2,215 crore, marking a 235% increase compared to the previous year. With this rapid scaling, the introduction of a national monograph is intended to ensure that all manufacturers, regardless of their production methods, adhere to consistent safety and quality benchmarks.
Because semaglutide is a complex peptide molecule, it requires precise manufacturing conditions, including sophisticated cell culture techniques. Previously, manufacturers largely relied on internal protocols or international standards. By establishing indigenous IP monographs, the government aims to reduce testing costs and provide a clear regulatory framework for both domestic and multinational firms operating in India.
While the expansion of the market has made treatment more accessible, it has also introduced specific challenges. Regulatory bodies have previously raised concerns regarding the unsupervised use of prescription-only GLP-1 medications and misleading surrogate advertising. Additionally, the complexity of cold-chain logistics for injectable biologics poses a persistent risk for product efficacy. The new standards are expected to help state regulators identify and curb the entry of counterfeit or sub-standard products into the supply chain.
For investors and market observers, the key monitorable will be how effectively pharmaceutical companies align their production processes with these incoming standards. As the government continues to increase oversight, the focus remains on ensuring that the rapid increase in generic availability does not compromise patient safety or product efficacy.